Screener
Immunome IMNM Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Immunome’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219425
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total assets | $619,792 | $683,188 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $5,534 | $3,339 |
| Accrued expenses and other current liabilities | 21,878 | 41,651 |
| Total current liabilities | 27,412 | 44,990 |
| Operating lease liabilities, net of current portion | 3,694 | 3,855 |
| Total liabilities | 31,106 | 48,845 |
Item 1. Financial Statements.
FAQ
- What is Immunome's accounts payable?
- Immunome (IMNM) reported accounts payable of $5.53M in Q1 2026.
- How has Immunome's accounts payable changed year-over-year?
- Immunome's accounts payable decreased by 39.4% year-over-year, from $9.13M to $5.53M.
- What is the long-term trend for Immunome's accounts payable?
- Over 4 years (2021 to 2025), Immunome's accounts payable has grown at a 20.3% compound annual growth rate (CAGR), from $11.1M to $23.27M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Immunome's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude